When to Use N-Acetylcysteine for Acute Hepatitis
N-acetylcysteine (NAC) should be administered immediately in ALL cases of acute liver failure (ALF) when acetaminophen toxicity is known, suspected, or cannot be ruled out, and should be strongly considered for non-acetaminophen ALF regardless of etiology. 1
Acetaminophen-Induced Acute Liver Failure
Begin NAC promptly without waiting for acetaminophen levels in any patient with:
- Known or suspected acetaminophen overdose 2, 1, 3
- Rising aminotransferases suggesting evolving liver injury 2
- AST/ALT levels exceeding 3,500 IU/L (highly correlated with acetaminophen poisoning even without clear history) 2
- Uncertain history or inadequate knowledge of circumstances surrounding admission 2
Critical Timing Considerations
- Most effective when started within 8-10 hours of ingestion 4
- Still beneficial up to 48 hours or more after ingestion 2
- Even late administration (>72 hours) can reverse hepatic failure 5
The AASLD guidelines explicitly state that NAC is recommended "in any case of ALF in which acetaminophen overdose is a suspected or possible cause" 2. This is a strong recommendation because acetaminophen is the leading cause of ALF in the United States and Europe, and low or absent acetaminophen levels do not rule out toxicity when ingestion timing is remote or unknown 2.
Non-Acetaminophen Acute Liver Failure
NAC should be initiated in non-acetaminophen ALF to improve transplant-free survival and overall outcomes. 1
The 2020 French guidelines provide a GRADE 2+ recommendation for NAC in all ALF regardless of etiology 1. This is supported by:
- Improved transplant-free survival: 64% vs 26% (OR = 4.81) 1
- Improved overall survival: 76% vs 59% (OR = 2.30) 1
- Reduced progression to severe encephalopathy 1
- Shorter hospital stays 6
Evidence Quality Nuance
While the 2017 AGA guidelines recommend NAC only in clinical trials for non-acetaminophen ALF 7, the more recent 2020 French guidelines 1 and multiple meta-analyses 6 support broader use. The benefit appears greatest in patients with grade I-II encephalopathy 1, suggesting NAC should be started early before progression to advanced stages.
Dosing Regimens
Intravenous (Preferred in ALF)
- Loading dose: 150 mg/kg in 5% dextrose over 15 minutes
- Maintenance: 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours 2
Oral (if IV not feasible)
- Loading dose: 140 mg/kg
- Maintenance: 70 mg/kg every 4 hours for 17 doses 2
IV administration is preferred in ALF because oral administration may be precluded by gastrointestinal bleeding, worsening mental status, or encephalopathy 2.
Mechanism of Benefit
NAC works through multiple pathways:
- Replenishes hepatic glutathione stores 3
- Acts as alternative substrate for conjugation with toxic metabolites 3
- Improves oxygen delivery and consumption (increases cardiac index from 5.6 to 6.7 L/min/m²) 8
- Reduces pro-inflammatory cytokines, particularly IL-17 9
- Decreases progression to hepatorenal syndrome 10
Safety Profile
NAC is remarkably safe with minimal side effects:
- Nausea, vomiting (occasional) 2
- Urticaria or bronchospasm (rare, <5% and 1-2% respectively) 1
- Allergic reactions managed with discontinuation, antihistamines, and epinephrine 2
Critical Pitfalls to Avoid
- Don't wait for acetaminophen levels before starting NAC in suspected cases 1
- Don't assume negative acetaminophen levels rule out toxicity - ingestion may be remote or unintentional over several days 2
- Don't delay NAC in patients with very high transaminases (>3,500 IU/L) even without clear acetaminophen history 2
- Don't withhold NAC in non-acetaminophen ALF - evidence supports benefit across etiologies 1
- Start NAC early - benefit is greatest in grade I-II encephalopathy before progression 1